What is the clinical evidence from this study?

Study design: RCT. Population: Coronary microembolization-induced myocardial damage (n=40). Intervention: Resveratrol vs. CME alone and sham. Primary outcome: Cardiac muscle function, myocardial injury markers, and pyroptosis-related molecules.

What does this research mean for the field?

Resveratrol pretreatment reduces the severity of myocardial injury after coronary microembolization by improving cardiac dysfunction and decreasing cardiomyocyte pyroptosis through the inhibition of TLR4/MyD88/NF-κB signaling and NLRP3 inflammasome activation. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

February 23, 2023Korean Journal of Physiology and PharmacologyOpen Access

Resveratrol pretreatment alleviates NLRP3 inflammasome-mediated cardiomyocyte pyroptosis by targeting TLR4/MyD88/NF-κB signaling cascade in coronary microembolization-induced myocardial damage

View Full Paper

Ask AI

Bookmark

Key result

Resveratrol pretreatment reduces myocardial injury after coronary microembolization by decreasing cardiomyocyte pyroptosis.

n=40

Why the study?

Resveratrol has demonstrated cardioprotective effects in various cardiac diseases, but its function and mechanisms in coronary microembolization remained unclear.

Does resveratrol pretreatment alleviate coronary microembolization-induced myocardial damage and pyroptosis in a rat model?

Population

Forty Sprague-Dawley rats

Comparison

CME vs CME + RES (25 mg/kg) vs CME + RES (50 mg/kg) vs sham

Design

Randomized preclinical animal study

Authors

CLChangjun LuoGuilin University of Technology TLTao LiQingdao University HLHaoliang LiUniversity of Shanghai for Science and Technology

Discussion

Member takes

Implication

No clinical implications for CME; leaves open translation of rat findings to human trials.

Study Design

Type

RCT (n=40)

Randomization

Randomly divided

Structured PICO

Does resveratrol pretreatment alleviate coronary microembolization-induced myocardial damage and pyroptosis in a rat model?

Population

40 Sprague-Dawley rats

Intervention

Resveratrol (RES) pretreatment at 25 mg/kg or 50 mg/kg

Comparator

Coronary microembolization (CME) model without resveratrol, and sham group

Outcome

Cardiac muscle function (echocardiography), serum myocardial injury markers, myocardial histopathology, and expression of pyroptosis-related molecules and TLR4/MyD88/NF-κB signalingsurrogate

Resveratrol pretreatment alleviates coronary microembolization-induced myocardial damage and pyroptosis in rats by inhibiting the TLR4/MyD88/NF-κB signaling pathway and NLRP3 inflammasome activation.

Cite This Study

Luo et al. (2023) conducted an RCT in Coronary microembolization-induced myocardial damage (n=40). Resveratrol vs. CME alone and sham was evaluated on Cardiac muscle function, myocardial injury markers, and pyroptosis-related molecules. Resveratrol pretreatment reduced the severity of myocardial injury after coronary microembolization by improving cardiac dysfunction and decreasing cardiomyocyte pyroptosis.

synapsesocial.com/papers/6a14b3acda53ecb65fb6ebb4 https://doi.org/10.4196/kjpp.2023.27.2.143

View Full Paper

Ask AI

Bookmark

Resveratrol pretreatment alleviates NLRP3 inflammasome-mediated cardiomyocyte pyroptosis by targeting TLR4/MyD88/NF-κB signaling cascade in coronary microembolization-induced myocardial damage

Discussion

Member takes

Implication

Study Design

Structured PICO

Cite This Study

Resveratrol pretreatment alleviates NLRP3 inflammasome-mediated cardiomyocyte pyroptosis by targeting TLR4/MyD88/NF-κB signaling cascade in coronary microembolization-induced myocardial damage

Discussion

Member takes

Implication

Study Design

Structured PICO

Cite This Study

Also Consider

Also Consider